NCT06164574View on ClinicalTrials.gov

Immunotherapy in Uncommon and 20ins EGFR-mut Lung Cancers

CompletedOBSERVATIONAL
Enrollment

627

Participants

Timeline

Start Date

November 1, 2022

Primary Completion Date

November 1, 2023

Study Completion Date

November 29, 2023

Conditions
Lung Cancer
Interventions
OTHER

Survival analysis

Immunotheray responses and long-term survival were evaluated in classical and other EGFR-mutant lung adenocarcinomas

Trial Locations (1)

200032

Chaoqiang Deng, Shanghai

All Listed Sponsors
lead

Haiquan Chen

OTHER